You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Innovative Filters Using Nanomaterials for Removal of Gaseous Pollutants and Particulates from Contaminated Air Streams

    SBC: ETSVP-JV, LLC            Topic: D

    A uniquely qualified team consisting of ETSVP-JV, a small business joint venture, and subcontractor RTI International, brings together all of the skills and experience needed for the development and testing of innovative nanomaterial filters. For this Phase I SBIR project, we propose to develop a dual-stage nanoporous filter media for controlling PM2.5 and volatile organic compounds (VOCs). Materi ...

    SBIR Phase I 2014 Environmental Protection Agency
  2. Low-Cost, Regenerable Air Filter for Efficient Gaseous Pollutants Removal

    SBC: PRECISION COMBUSTION, INC.            Topic: D

    Precision Combustion, Inc. (PCI) proposes to develop a regenerable, low-cost, high-efficiency pollution control technology for removal of gaseous pollutants from contaminated air streams. This innovative air filter technology will combine our novel proprietary Microlith® support elements with sorbent nanomaterials that can be tailored to capture a variety of targeted gaseous pollutants. Originall ...

    SBIR Phase I 2014 Environmental Protection Agency
  3. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Formulation of LbL microparticle vaccine in microneedle array for intradermal del

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    Abstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-retroviral therapy (ARV) consists of a cocktail of drugsthat blocks viral binding and replication, but does not destroy the HIV-1 provirus. In addition, ARV does not impact the large reservoir of laten ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical Studies of PG70 LEAPS Peptide Vaccines for Rheumatoid Arthritis

    SBC: CEL-SCI CORPORATION            Topic: NIAMS

    DESCRIPTION (provided by applicant): Currently, FDA-licensed pharmaceuticals used to treat rheumatoid arthritis (RA) focus largely on alleviation of symptoms, either through pain management, general immunosuppression, or by antagonizing cytokines such as TNF-?. Despite recent advances in biologic therapies, these treatments do not address the underlying autoimmune condition. Ligand epitope antigen ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Synergy between MAG-1 and Cyclophosphamide for Treatment of Recurrent SCLC

    SBC: Woomera Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, MAG-1, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that a cancer -specific provasopressin antigen, called GRSA, present at the surface of these tumors will prov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Assessment of Hypercoagulability in Cancer Patients Using Sonorheometry

    SBC: HEMOSONICS            Topic: NCI

    DESCRIPTION (provided by applicant): The Problem: Venous thromboembolism (VTE), which encompasses the diseases of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and life-threatening problem amongst cancer patients. In population-basedstudies, cancer has been associated with a 4-fold increase risk for VTE; in cancer patients undergoing systemic chemotherapy treatment the risk i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Dampening CAR therapy-induced cytokine storm with anti-GM-CSF antibodies

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term aim of this project is to reduce or eliminate the serious adverse events associated with cellular immunotherapy used to treat cancer. The current impressive efficacy of chimeric antigen receptor (CAR) T cell therapies is often accompanied by a well-known toxicity stemming from the large release of cytokines from activated immune cells, known as a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Low-Cost User-Friendly Otoacoustic Emissions Probe

    SBC: CREARE LLC            Topic: NIDCD

    DESCRIPTION (provided by applicant): This proposal responds to the NIDCD special solicitation RFA-DC-12-004 for improving access to hearing healthcare. In particular, the NIDCD is seeking solutions to lower the cost of hearing healthcare and improve accessfor underserved populations (such as the disabled and communities with limited resource access). Technologies that achieve the initiative object ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government